PML on Rituximab — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — JC polyomavirus causing progressive multifocal leukoencephalopathy
Progressive multifocal leukoencephalopathy results from JC-virus reactivation during impaired cellular or humoral immunity. Rituximab must be withheld and urgent neurology, MRI and CSF JC-virus PCR assessment arranged.
Reference: BSR biologic DMARD safety guideline in inflammatory arthritis — executive summary (Published 2019; update in development): https://academic.oup.com/rheumatology/article/58/2/220/5076445; BNF: rituximab (Current BNF monograph, accessed 30 July 2026): https://bnf.nice.org.uk/drugs/rituximab/